Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.00

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $30.00.

Several research firms have weighed in on ATXS. Cantor Fitzgerald reissued an “overweight” rating and issued a $47.00 price target on shares of Astria Therapeutics in a report on Wednesday, May 14th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday, March 11th. JMP Securities began coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They set an “outperform” rating and a $26.00 target price on the stock. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 target price (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th.

Astria Therapeutics Stock Performance

Shares of ATXS stock opened at $4.29 on Friday. Astria Therapeutics has a 52 week low of $3.56 and a 52 week high of $12.92. The company has a market capitalization of $242.10 million, a price-to-earnings ratio of -2.05 and a beta of 0.45. The company has a 50-day simple moving average of $4.90 and a 200 day simple moving average of $7.27.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Sell-side analysts forecast that Astria Therapeutics will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new position in Astria Therapeutics in the fourth quarter valued at approximately $41,000. Tower Research Capital LLC TRC increased its stake in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Astria Therapeutics in the fourth quarter valued at approximately $50,000. Virtus ETF Advisers LLC bought a new position in Astria Therapeutics in the fourth quarter valued at approximately $65,000. Finally, GAMMA Investing LLC increased its stake in Astria Therapeutics by 1,127.4% in the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 7,971 shares during the last quarter. 98.98% of the stock is owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.